
Hello ,
Last week an interesting news story about >20 Texan patients treated with stem cells suffering from multiple sclerosis came out. We watch these developments with cautious optimism. Click here for the video.
A recent paper describing TNF-alpha inhibiting SDF-1 secretion was published. This may explain some of the osteoclastic effects seen in patients with chronic inflammation. Another interesting finding was that EPO can inhibit the mouse model of multiple sclerosis through stimulation of Treg and inhibition of Th17. Maybe this is why some cancer patients do worse if they are on chronic EPO?
Two neat patents came out last week. #7,494,644 covers the transfection of cells (myoblasts and mesenchymal) with connexin-43 to increase their ability to interact with myocardium. This could be a great way of overcoming arrythmias seen with some myoblast-based approaches. Irv Weissman continues his patent domination of the field of hematology, getting a patent on the megakaryocytic progenitor (#7,494,807). He is inventor on the common myeloid progenitor, as well as common lymphoid progenitor patents. Great job Irv !
Although the majority of studies looking at stem cell mediated immune modulation have been focused on mesenchymal stem cells, a recent paper describes suppression of the mouse model of MS through administration of hematopoietic stem cells, and demonstrated that therapeutic effect was associated with upregulation of indolamine 2,3 deoxygenase in the dendritic cells.
|
Patent Number: 7,494,644
It is known that bone marrow stem cells are mobilized after heart injury such as infarct, with presumable therapeutic effects mediated by the stem cells in terms of stimulating angiogenesis or even integrating into the damaged myocardium and transdifferentiating into de novo [Read More]
Ask a question OR leave your comments.
|
|
|
Media Partnerships (NEW)
Thanks again for your help in supporting StemCellPatents.com.
Media Partnerships (NEW)
(BETA)